Experts Endorse Barrier Films to Shield Skin From Radiation Burns in Cancer Therapy

For millions of people undergoing radiotherapy each year, the treatment that targets their tumor often leaves an unwelcome mark on their skin. Acute radiation dermatitis, the redness, itching, peeling, and sometimes painful breakdown of skin in the irradiated field, affects the vast majority of patients receiving external beam radiation, and in a substantial minority it becomes severe enough to cause treatment interruptions, infections, and lasting distress. Now, an international panel of specialists has issued a formal clinical practice statement offering practical, evidence-based guidance on one of the most promising preventive tools: barrier-forming topical agents, thin films that are painted onto the skin to protect it before the damage begins.

The statement, published in Supportive Care in Cancer by the Oncodermatology Study Group of the Multinational Association of Supportive Care in Cancer (MASCC), was led by Shirley S. W. Tse of the Hospital Authority in Hong Kong and Shely Kagan of the Odette Cancer Centre in Toronto, together with a multidisciplinary team of radiation oncologists, dermatologists, and nurses spanning North America, Europe, Asia, and Australia. Because high-quality trial evidence in this field remains limited, the authors chose the format of a clinical practice statement rather than a formal guideline: a practice-oriented document that distills expert consensus into actionable recommendations for clinicians who must make decisions today, even where the literature is incomplete.

To build the statement, the panel conducted a comprehensive review of the literature indexed in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, with the search extending up to April 23, 2026. The identified studies were then examined through structured discussions among the experts of the MASCC Oncodermatology Study Group, who synthesized their conclusions into a series of practical bullet points covering the entire clinical pathway: which patients should be considered for prophylaxis, how the skin should be prepared, which product to choose, how and how often to apply it, and how patients should be monitored from the start of treatment through to the discontinuation of the agent.

The biological rationale behind barrier-forming agents is rooted in the pathophysiology of radiation dermatitis itself. Ionizing radiation damages the rapidly dividing basal cells of the epidermis and triggers an inflammatory cascade that peaks in the weeks following exposure. Friction, moisture, and mechanical stress on already compromised skin accelerate the deterioration from faint erythema to moist desquamation, the wet, raw breakdown that clinicians most want to avoid. Barrier films and film-forming silicone gels work by creating a thin, flexible, semi-occlusive layer over the stratum corneum, reducing friction and shear forces, limiting transepidermal water loss, and shielding vulnerable skin folds and irregular contours where sweat and movement concentrate injury. Unlike thick ointments, these products are designed not to interfere with the radiation beam itself, a critical consideration that has historically made oncologists wary of applying anything to the skin during a treatment course.

The central recommendation of the statement is deliberately targeted rather than universal. The panel recommends barrier-forming topical agents for patients undergoing radiotherapy who are at considerable risk of developing high-grade radiation dermatitis, with a particular emphasis on treatment sites that have irregular anatomical contours. Head and neck cancer patients, whose skin must tolerate radiation across curved, mobile, and often moist surfaces around the jaw, neck, and behind the ears, emerge as the clearest beneficiaries. The panel notes that extension of prophylaxis to other anatomical subsites may be considered, but cautions that more robust data are required before routine use can be endorsed in those settings, a position that reflects both the promise of the technology and the honest limits of the current evidence base.

Among the available products, one stands out in the panel’s assessment. StrataXRT, a silicone-based film-forming gel dressing, currently has the most robust supporting evidence, according to the statement. That conclusion rests on a growing body of clinical research, including a single-blind randomized controlled trial published in Radiotherapy and Oncology in 2019, in which Chan and colleagues tested the gel as prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Subsequent work has extended the evaluation to breast cancer, including a 2025 intrapatient noninferiority randomized clinical trial by Lee and colleagues, published in the International Journal of Radiation Oncology, Biology, Physics, which compared StrataXRT with Mepitel Film, a silicone mesh film, for preventing postmastectomy radiation dermatitis. The intrapatient design, in which different areas of the same patient’s skin receive different interventions, is particularly powerful because it controls for individual differences in radiation sensitivity, skin type, and treatment parameters.

The broader literature reviewed by the panel spans more than two decades of experimentation with skin protection during radiotherapy. Early paired-comparison trials, such as the 2004 study by Graham and colleagues in the Trans Tasman Radiation Oncology Group, tested no-sting barrier films against conventional sorbolene cream in postmastectomy patients, while later studies evaluated barrier creams, moisturizers, and topical corticosteroids such as mometasone furoate. A 2024 systematic review and network meta-analysis by Wong and colleagues in Breast Cancer Research and Treatment synthesized the comparative evidence on barrier films and dressings in breast cancer, and a 2026 meta-analysis by the same group directly compared Mepitel Film with StrataXRT in postmastectomy radiotherapy. Health economics has entered the picture as well: a 2026 Canadian cost-effectiveness analysis of Mepitel Film for breast cancer patients, published in Breast Cancer Research and Treatment, examined whether the upfront cost of prophylactic films is offset by the avoided costs of managing severe dermatitis, including unplanned clinical visits, dressings, and treatment delays.

The practical guidance embedded in the statement addresses questions that clinicians confront daily but that trial reports rarely answer. When should application begin, and how long should it continue? How should the skin be cleansed and prepared so the film adheres properly? What technique ensures an even layer without pooling in skin folds? How should clinicians reconcile the application schedule with radiotherapy sessions, and what signs should trigger reassessment or discontinuation? By structuring its recommendations around patient selection, skin preparation, product choice, application schedule and technique, and ongoing monitoring, the panel has effectively created a checklist that radiation oncology departments can adapt to their own workflows, from high-volume breast cancer services to complex head and neck programs.

The significance of the statement extends beyond its specific recommendations. Radiation dermatitis has long been treated as an inevitable side effect, managed reactively after redness appears rather than prevented proactively. The 2023 MASCC Delphi consensus recommendations published in The Lancet Oncology marked a first step toward standardized prevention and management of the condition; the new practice statement builds on that foundation by drilling down into one specific class of preventive agents and codifying how they should be used. The oncodermatology discipline itself, sitting at the intersection of cancer medicine and dermatology, has grown rapidly as survival rates improve and the long-term quality of life of cancer patients becomes a central measure of treatment success.

For patients, the message is that skin protection during radiotherapy is no longer a matter of folklore and improvised moisturizing, but an evolving clinical science with specific tools, defined protocols, and an evidence hierarchy. For clinicians, the statement offers a defensible consensus position in an area where definitive trial data remain sparse: reserve barrier-forming topical agents for those at considerable risk of high-grade dermatitis, prioritize sites with irregular contours such as the head and neck, and lean on StrataXRT where the evidence is strongest, while recognizing that broader routine use awaits stronger data. As radiotherapy techniques grow more precise and hypofractionated schedules become standard, the interplay between beam physics and skin biology will continue to evolve, and statements like this one provide the framework through which new evidence can be rapidly translated into everyday cancer care.

Subject of Research: Prevention of acute radiation dermatitis with barrier-forming topical agents during radiotherapy

Article Title: MASCC oncodermatology clinical practice statement: prevention of acute radiation dermatitis using barrier-forming topical agents

Article References: Tse, S. S. W., Kagan, S., Zhang, B., Yang, C., Verma, S., Wong, H. C. Y., Lee, S. F., Wolf, J. R., van den Hurk, C., Chan, R. J., Herst, P. M., Hijal, T., Bolivar, C. H. A., Chow, E., Bonomo, P., Marta, G. N., & on behalf of the Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group (2026). MASCC oncodermatology clinical practice statement: prevention of acute radiation dermatitis using barrier-forming topical agents. Supportive Care in Cancer, 34(10), Article 1057. https://doi.org/10.1007/s00520-026-11244-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11244-2

Keywords: acute radiation dermatitis, radiotherapy, barrier-forming topical agents, StrataXRT, oncodermatology, MASCC, clinical practice statement, supportive care in cancer, skin toxicity, head and neck cancer, breast cancer, silicone film-forming gel